Repare Therapeutics IncNASDAQ:RPTX
- LAST PRICE3.5700
- TODAY'S CHANGE (%)-0.1200 (-3.2520%)
- Bid / Lots3.5000/ 40
- Ask / Lots3.8500/ 40
- Open / Previous Close3.7500 / 3.6900
- Day Range
- 52 Week Range
- Volume182,419
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPTX |
|---|---|---|
| 09:32 ET | 1878 | 3.75 |
| 09:34 ET | 500 | 3.7148 |
| 09:36 ET | 699 | 3.78 |
| 09:38 ET | 5840 | 3.75 |
| 09:39 ET | 400 | 3.75 |
| 09:41 ET | 200 | 3.76 |
| 09:43 ET | 790 | 3.78 |
| 09:45 ET | 1100 | 3.76 |
| 09:48 ET | 200 | 3.78 |
| 09:50 ET | 200 | 3.78 |
| 09:52 ET | 160 | 3.78 |
| 09:54 ET | 1422 | 3.7947 |
| 09:56 ET | 997 | 3.7598 |
| 09:57 ET | 200 | 3.8 |
| 09:59 ET | 1239 | 3.74 |
| 10:06 ET | 100 | 3.755 |
| 10:08 ET | 206 | 3.75 |
| 10:10 ET | 759 | 3.75 |
| 10:12 ET | 2000 | 3.74 |
| 10:14 ET | 1775 | 3.72 |
| 10:15 ET | 100 | 3.72 |
| 10:17 ET | 18552 | 3.68 |
| 10:19 ET | 300 | 3.68 |
| 10:21 ET | 600 | 3.7 |
| 10:26 ET | 200 | 3.68 |
| 10:28 ET | 100 | 3.67 |
| 10:30 ET | 1900 | 3.65 |
| 10:32 ET | 200 | 3.6413 |
| 10:46 ET | 100 | 3.64 |
| 10:48 ET | 200 | 3.67 |
| 10:50 ET | 100 | 3.66 |
| 10:51 ET | 1000 | 3.6699 |
| 10:53 ET | 100 | 3.66 |
| 11:02 ET | 1944 | 3.64 |
| 11:06 ET | 700 | 3.6 |
| 11:08 ET | 300 | 3.61 |
| 11:11 ET | 1301 | 3.6 |
| 11:15 ET | 2361 | 3.5911 |
| 11:20 ET | 600 | 3.5801 |
| 11:24 ET | 400 | 3.6 |
| 11:26 ET | 200 | 3.6 |
| 11:29 ET | 300 | 3.6 |
| 11:31 ET | 413 | 3.6 |
| 11:36 ET | 453 | 3.59 |
| 11:40 ET | 500 | 3.58 |
| 11:44 ET | 3224 | 3.59 |
| 11:45 ET | 100 | 3.59 |
| 11:47 ET | 400 | 3.59 |
| 11:51 ET | 100 | 3.59 |
| 11:54 ET | 100 | 3.6 |
| 11:56 ET | 3870 | 3.59 |
| 11:58 ET | 200 | 3.6 |
| 12:00 ET | 300 | 3.6 |
| 12:02 ET | 500 | 3.59 |
| 12:07 ET | 1100 | 3.58 |
| 12:18 ET | 505 | 3.565 |
| 12:20 ET | 600 | 3.54 |
| 12:21 ET | 9061 | 3.535 |
| 12:23 ET | 200 | 3.525 |
| 12:25 ET | 500 | 3.54 |
| 12:27 ET | 300 | 3.54 |
| 12:30 ET | 6230 | 3.555 |
| 12:32 ET | 200 | 3.57 |
| 12:34 ET | 200 | 3.58 |
| 12:36 ET | 200 | 3.58 |
| 12:39 ET | 100 | 3.57 |
| 12:41 ET | 100 | 3.585 |
| 12:45 ET | 208 | 3.585 |
| 12:48 ET | 125 | 3.5954 |
| 12:50 ET | 1250 | 3.59 |
| 12:54 ET | 100 | 3.595 |
| 12:56 ET | 611 | 3.59 |
| 12:57 ET | 513 | 3.56 |
| 12:59 ET | 370 | 3.575 |
| 01:03 ET | 2540 | 3.575 |
| 01:06 ET | 100 | 3.58 |
| 01:10 ET | 100 | 3.585 |
| 01:14 ET | 100 | 3.585 |
| 01:21 ET | 100 | 3.58 |
| 01:24 ET | 1100 | 3.59 |
| 01:35 ET | 100 | 3.59 |
| 01:39 ET | 100 | 3.6 |
| 01:42 ET | 355 | 3.58 |
| 01:44 ET | 740 | 3.59 |
| 01:48 ET | 100 | 3.59 |
| 01:51 ET | 2620 | 3.575 |
| 01:53 ET | 426 | 3.57 |
| 02:00 ET | 137 | 3.5634 |
| 02:04 ET | 100 | 3.56 |
| 02:06 ET | 1220 | 3.5631 |
| 02:08 ET | 4326 | 3.53 |
| 02:09 ET | 3720 | 3.57 |
| 02:11 ET | 500 | 3.56 |
| 02:15 ET | 700 | 3.56 |
| 02:18 ET | 700 | 3.555 |
| 02:20 ET | 100 | 3.5401 |
| 02:26 ET | 600 | 3.55 |
| 02:27 ET | 518 | 3.55 |
| 02:31 ET | 100 | 3.55 |
| 02:33 ET | 637 | 3.53 |
| 02:36 ET | 300 | 3.535 |
| 02:38 ET | 1128 | 3.515 |
| 02:40 ET | 1975 | 3.525 |
| 02:42 ET | 1049 | 3.53 |
| 02:44 ET | 4798 | 3.53 |
| 02:45 ET | 700 | 3.55 |
| 02:51 ET | 1221 | 3.565 |
| 02:54 ET | 400 | 3.58 |
| 02:56 ET | 200 | 3.585 |
| 02:58 ET | 600 | 3.5887 |
| 03:02 ET | 300 | 3.58 |
| 03:07 ET | 3451 | 3.59 |
| 03:09 ET | 200 | 3.575 |
| 03:12 ET | 200 | 3.59 |
| 03:16 ET | 2751 | 3.54 |
| 03:18 ET | 4965 | 3.55 |
| 03:21 ET | 500 | 3.56 |
| 03:23 ET | 695 | 3.56 |
| 03:30 ET | 714 | 3.555 |
| 03:32 ET | 1200 | 3.53 |
| 03:34 ET | 1454 | 3.53 |
| 03:36 ET | 818 | 3.57 |
| 03:38 ET | 341 | 3.555 |
| 03:39 ET | 683 | 3.5442 |
| 03:41 ET | 800 | 3.57 |
| 03:43 ET | 421 | 3.555 |
| 03:45 ET | 1410 | 3.55 |
| 03:48 ET | 393 | 3.5401 |
| 03:50 ET | 1079 | 3.54 |
| 03:54 ET | 1220 | 3.56 |
| 03:56 ET | 741 | 3.5422 |
| 03:57 ET | 1300 | 3.55 |
| 03:59 ET | 6554 | 3.57 |
May 8, 2024
DJ Repare Therapeutics Shares Rise 17% After 1Q Earnings, Revenue Beats, from 12:34PM ET on Wednesday May 08, 2024 by Dow Jones
12:34PM ET on Wednesday May 08, 2024 by Dow Jones
May 7, 2024
*DJ Repare Therapeutics 1Q EPS 30c >RPTX, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow JonesRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones
Apr 30, 2024
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition, from 7:05AM ET on Tuesday Apr 30, 2024 by Dow Jones
7:05AM ET on Tuesday Apr 30, 2024 by Dow JonesDebiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition, from 7:05AM ET on Tuesday Apr 30, 2024 by Dow Jones
7:05AM ET on Tuesday Apr 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Repare Therapeutics Inc | 156.6M | -3.3x | --- |
AVITA Medical Inc | 225.0M | -4.7x | --- |
Genfit SA | 183.9M | -6.0x | --- |
Precision BioSciences Inc | 80.4M | -2.2x | --- |
Champions Oncology Inc | 63.1M | -6.7x | --- |
Innate Pharma SA | 202.8M | -24.7x | --- |
Company Information
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
Contact Information
- Headquarters
- 7210 Frederick-Banting, Suite 100ST-LAURENT, QC, Canada H4S 2A1
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Thomas Civik
- President, Chief Executive Officer, Director
- Lloyd Segal
- Chief Financial Officer, Executive Vice President
- Steve Forte
- Executive Vice President, Chief Scientific Officer
- Michael Zinda
- Executive Vice President, Chief Medical Officer
- Maria Koehler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $156.6M |
|---|---|
Revenue (TTM) | $97.9M |
Shares Outstanding | 42.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.74 |
EPS | $-1.10 |
Book Value | $5.03 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -72.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
